Skip to main content

Articles By John Swope

PSA068.jpg

FUTURE 2 Trial Shows Secukinumab to be Effective in Psoriatic Arthritis

Lancet today published the results of the phase 3, prospecitive, multinational, double-blind, randomized controlled trial of secukinumab (an anti-IL-17A monoclonal antibody) in active psoriatic arthritis.

Read Article